|
|
Blood, 15 September 2006, Vol. 108, No. 6, pp. 2114-2120.
Prepublished online as a Blood First Edition Paper on May 11, 2006; DOI 10.1182/blood-2005-11-011650.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting
Alma J. Nauta,
Geert Westerhuis,
Alwine B. Kruisselbrink,
Ellie G. A. Lurvink,
Roel Willemze, and
Willem E. Fibbe
From the Laboratory of Experimental Hematology, Department of Hematology, Leiden University Medical Center, The Netherlands.
Mesenchymal stem cells (MSCs) are multipotent progenitor cells that have emerged as a promising tool for clinical application. Further clinical interest has been raised by the observation that MSCs are immunoprivileged and, more important, display immunosuppressive capacities. These properties may be of therapeutic value in allogeneic transplantation to prevent graft rejection and to prevent and treat graft-versus-host disease. In the present study, we examined the in vivo immunomodulatory properties of MSCs in murine models of allogeneic bone marrow (BM) transplantation. Sublethally irradiated recipients received allogeneic BM with or without host or donor MSCs. The addition of host MSCs significantly enhanced the long-term engraftment associated with tolerance to host and donor antigens. However, the infusion of donor MSCs was associated with significantly increased rejection of allogeneic donor BM cells. Moreover, we showed that the injection of merely allogeneic donor MSCs in naive mice was sufficient to induce a memory T-cell response. Although the observed engraftment-promoting effects of host MSCs in vivo support the therapeutic potential of MSCs, our results also indicate that allogeneic MSCs are not intrinsically immunoprivileged and that under appropriate conditions, allogeneic MSCs induce a memory T-cell response resulting in rejection of an allogeneic stem cell graft.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. E.J. Reinders, W. E. Fibbe, and T. J. Rabelink
Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation
Nephrol. Dial. Transplant.,
October 26, 2009;
(2009)
gfp552v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Quevedo, K. E. Hatzistergos, B. N. Oskouei, G. S. Feigenbaum, J. E. Rodriguez, D. Valdes, P. M. Pattany, J. P. Zambrano, Q. Hu, I. McNiece, et al.
Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity
PNAS,
August 18, 2009;
106(33):
14022 - 14027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fiorina, M. Jurewicz, A. Augello, A. Vergani, S. Dada, S. La Rosa, M. Selig, J. Godwin, K. Law, C. Placidi, et al.
Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes
J. Immunol.,
July 15, 2009;
183(2):
993 - 1004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wang, W. Ge, J. Arp, R. Zassoko, W. Liu, T. E. Ichim, J. Jiang, A. M. Jevnikar, and B. Garcia
Free Bone Graft Attenuates Acute Rejection and in Combination with Cyclosporin A Leads to Indefinite Cardiac Allograft Survival
J. Immunol.,
May 15, 2009;
182(10):
5970 - 5981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Vela, G. V. Silva, J. A.R. Assad, A. L.S. Sousa, S. Coulter, M. R. Fernandes, E. C. Perin, J. T. Willerson, and L. M. Buja
Histopathological Study of Healing After Allogenic Mesenchymal Stem Cell Delivery in Myocardial Infarction in Dogs
J. Histochem. Cytochem.,
February 1, 2009;
57(2):
167 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Haniffa, M. P. Collin, C. D. Buckley, and F. Dazzi
Mesenchymal stem cells: the fibroblasts' new clothes?
Haematologica,
February 1, 2009;
94(2):
258 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Proceedings of the ATS,
July 15, 2008;
5(5):
637 - 667.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Atoui, D. Shum-Tim, and R. C.J. Chiu
Myocardial Regenerative Therapy: Immunologic Basis for the Potential "Universal Donor Cells"
Ann. Thorac. Surg.,
July 1, 2008;
86(1):
327 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh
Immunomodulation by Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Type 1 Diabetes
Diabetes,
July 1, 2008;
57(7):
1759 - 1767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M-C Kastrinaki, P Sidiropoulos, S Roche, J Ringe, S Lehmann, H Kritikos, V-M Vlahava, B Delorme, G D Eliopoulos, C Jorgensen, et al.
Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis
Ann Rheum Dis,
June 1, 2008;
67(6):
741 - 749.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Sadek and D. J. Garry
Letter by Sadek and Garry Regarding Article, "Iron-Oxide Labeling and Outcome of Transplanted Mesenchymal Stem Cells in the Infarcted Myocardium"
Circulation,
April 8, 2008;
117(14):
e306 - e306.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Larghero, D Farge, A Braccini, S Lecourt, A Scherberich, E Fois, F Verrecchia, T Daikeler, E Gluckman, A Tyndall, et al.
Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis
Ann Rheum Dis,
April 1, 2008;
67(4):
443 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nauta and W. E. Fibbe
Immunomodulatory properties of mesenchymal stromal cells
Blood,
November 15, 2007;
110(10):
3499 - 3506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chabannes, M. Hill, E. Merieau, J. Rossignol, R. Brion, J. P. Soulillou, I. Anegon, and M. C. Cuturi
A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells
Blood,
November 15, 2007;
110(10):
3691 - 3694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Rasmusson, M. Uhlin, K. Le Blanc, and V. Levitsky
Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes
J. Leukoc. Biol.,
October 1, 2007;
82(4):
887 - 893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sundin, O. Ringden, B. Sundberg, S. Nava, C. Gotherstrom, and K. Le Blanc
No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients
Haematologica,
September 1, 2007;
92(9):
1208 - 1215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Romieu-Mourez, M. Francois, M.-N. Boivin, J. Stagg, and J. Galipeau
Regulation of MHC Class II Expression and Antigen Processing in Murine and Human Mesenchymal Stromal Cells by IFN-{gamma}, TGF-beta, and Cell Density
J. Immunol.,
August 1, 2007;
179(3):
1549 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Haniffa, X.-N. Wang, U. Holtick, M. Rae, J. D. Isaacs, A. M. Dickinson, C. M. U. Hilkens, and M. P. Collin
Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells
J. Immunol.,
August 1, 2007;
179(3):
1595 - 1604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Locatelli, R. Maccario, and F. Frassoni
Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders?
Haematologica,
July 1, 2007;
92(7):
872 - 877.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Aydin, A. J. van Zonneveld, J. W. de Fijter, and T. J. Rabelink
New horizons in prevention and treatment of ischaemic injury to kidney transplants
Nephrol. Dial. Transplant.,
February 1, 2007;
22(2):
342 - 346.
[Full Text]
[PDF]
|
|
|
|
|
